# HistoSonics Secures $2.25 Billion Investment Led by Jeff Bezos for Non-Invasive Ultrasound Tumor Treatment

> financing · REPORTED · 2026-07-01

HistoSonics secured a $2.25 billion investment led by Jeff Bezos and others for its FDA-cleared non-invasive ultrasound tumor treatment technology, with plans to expand beyond liver tumors to kidney, pancreas, and prostate applications while accelerating U.S. and global growth.

About HistoSonics: HistoSonics is a medical device company developing histotripsy technology, an FDA-cleared non-invasive ultrasound-based treatment that uses precisely controlled acoustic energy to destroy tumors without incisions, heat, or radiation.

- Company: HistoSonics
- Sector: medtech
- Primary source: https://www.mddionline.com/business/ma

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.